Developing the Next Generation PD-L1 Assays Using Precision Mass Spectrometry

Principal Investigator: Christoph Borchers
Theme : Health
Competition : Genome Canada competition - Genomic Applications Partnership Program (GAPP)
Status : Completed
Start : Apr. 1, 2019
End: Mar. 31, 2022
Budget : $1,449,026.00

Lung cancer accounts for 14% of all diagnosed cancers in Canada from which 80% will be tested for programmed cell death protein 1 (PD-L1) through the course of the disease.  This project aims to develop PD-L1 Mass Spectrometry (MS)-based assays for use in immune-oncology. The Receptor, MRM Proteomics, in partnership with the academic leaders, will develop two alternative analytical pipelines based on multiple reaction monitoring (MRM, for research purposes) and immuno MALDI (iMALDI technology, suitable for clinical diagnostics). The anticipated revenues for MRMP’s new PD-L1 kit is projected as $3.5 million over the first 5 years plus the addition of the iMALDI technology to 20% of PD-L1 testing would generate more than $250 million.


Lead Genome Centre: Génome Québec 

Co-project leaders:

Alan Spatz

Lady Davis Institute, Jewish General Hospital

Claude Leduc

MRM Proteomics